GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioGaia AB (OTCPK:BIOGY) » Definitions » ROCE %

BioGaia AB (BioGaia AB) ROCE % : 16.99% (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is BioGaia AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BioGaia AB's annualized ROCE % for the quarter that ended in Dec. 2023 was 16.99%.


BioGaia AB ROCE % Historical Data

The historical data trend for BioGaia AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioGaia AB ROCE % Chart

BioGaia AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.04 20.22 12.91 20.91 22.56

BioGaia AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.98 28.67 19.77 25.52 16.99

BioGaia AB ROCE % Calculation

BioGaia AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=45.785/( ( (213.333 - 15.898) + (227.46 - 19.082) )/ 2 )
=45.785/( (197.435+208.378)/ 2 )
=45.785/202.9065
=22.56 %

BioGaia AB's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=33.696/( ( (207.875 - 19.62) + (227.46 - 19.082) )/ 2 )
=33.696/( ( 188.255 + 208.378 )/ 2 )
=33.696/198.3165
=16.99 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioGaia AB  (OTCPK:BIOGY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


BioGaia AB ROCE % Related Terms

Thank you for viewing the detailed overview of BioGaia AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioGaia AB (BioGaia AB) Business Description

Traded in Other Exchanges
Address
Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.